<code id='6CEC42F768'></code><style id='6CEC42F768'></style>
    • <acronym id='6CEC42F768'></acronym>
      <center id='6CEC42F768'><center id='6CEC42F768'><tfoot id='6CEC42F768'></tfoot></center><abbr id='6CEC42F768'><dir id='6CEC42F768'><tfoot id='6CEC42F768'></tfoot><noframes id='6CEC42F768'>

    • <optgroup id='6CEC42F768'><strike id='6CEC42F768'><sup id='6CEC42F768'></sup></strike><code id='6CEC42F768'></code></optgroup>
        1. <b id='6CEC42F768'><label id='6CEC42F768'><select id='6CEC42F768'><dt id='6CEC42F768'><span id='6CEC42F768'></span></dt></select></label></b><u id='6CEC42F768'></u>
          <i id='6CEC42F768'><strike id='6CEC42F768'><tt id='6CEC42F768'><pre id='6CEC42F768'></pre></tt></strike></i>

          fashion

          fashion

          author:knowledge    Page View:19377
          Adam's take main illustration
          Molly Ferguson/STAT

          Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise unscathed — happy to pay a small breakup fee to MorphoSys to avoid owning a drug for myelofibrosis that regulators turned away.

          MorphoSys will not fare as well from the breakup. Its future, and that of the drug called pelabresib at the center of the deal, will be thrown into limbo.

          advertisement

          This is all speculation on my part, but it’s supported by separate conversations with two people familiar with pelabresib and the debate inside Novartis over the MorphoSys acquisition. They requested anonymity to discuss confidential matters.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Sen. Paul opposes bill to ban Chinese biotechs
          Sen. Paul opposes bill to ban Chinese biotechs

          Sen.RandPaul(R-Ky.)WinMcNamee/GettyImagesWASHINGTON—ASenatepanelWednesdaypassedabillaimedatpreventin

          read more
          The high cost of giving birth even with insurance
          The high cost of giving birth even with insurance

          AdobeTheburdenofhighhealthcarecostsandmedicaldebtintheU.S.isnosecret.Medicaldebtaffectsoneinfiveadul

          read more

          WATCH: Why do our ears pop?

          Whatcausesourearstopopandwhataretheydoing,exactly?AlexHogan,MatthewOrr/STATTakingoffinanairplanealwa